Free Trial
NASDAQ:NEUP

Neuphoria Therapeutics Q1 2026 Earnings Report

Neuphoria Therapeutics logo
$4.84 +0.14 (+2.98%)
Closing price 04:00 PM Eastern
Extended Trading
$4.80 -0.04 (-0.72%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Neuphoria Therapeutics EPS Results

Actual EPS
-$4.41
Consensus EPS
-$0.55
Beat/Miss
Missed by -$3.86
One Year Ago EPS
N/A

Neuphoria Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Neuphoria Therapeutics Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Neuphoria Therapeutics Earnings Headlines

One page of the SpaceX S-1 will move this stock overnight
When SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including power consumption for 1 million GPUs, a cost that rivals entire cities. That disclosure will name the supplier. One small, publicly traded power infrastructure company sits at the center of this - carrying a $1.5 billion backlog and priced like a utility. Dylan Jovine has the full breakdown.tc pixel
See More Neuphoria Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Neuphoria Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Neuphoria Therapeutics and other key companies, straight to your email.

About Neuphoria Therapeutics

Neuphoria Therapeutics (NASDAQ:NEUP), Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

View Neuphoria Therapeutics Profile